Cypros bolsters its low cash burn strategy
Cypros bolsters its low cash burn strategy Although a number of biotech companies have brought multiple products into advanced clinical trials, few have accomplished the mission by spending less than Cypros Pharmaceutical Corp.
Since inception in November 1990, the Carlsbad, Calif., company has spent $7.5 million while moving its two small molecule drugs into five Phase II trials.
The 22-person company is developing CPC-111 and CPC-211 to treat disorders related to low blood flow. CPC-111 is in three Phase II trials to